Product Name: FGFR2 (808-821)
Product Number: PE-01AUG99
Size: 200 µg      Price:45.00
1 mg      $US90.00
5 mg      196.00
Peptide Name: FGFR2 (808-821)

Product Use: Services as a blocking peptide for use with the FGFR2 rabbit polyclonal antibody (Cat. No.: AB-NK063-2P) that is also available from Kinexus. The peptide sequence is located in the C-terminus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CLPQYPHINGSVKT

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Free carboxyl

Peptide Molecular Mass Calculated: 1555.77 Da

Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: FGFR2 pan-specific antibody (Cat. No.: AB-NK063-2P)

Scientific Background: FGFR2 (KGFR) is a protein-tyrosine kinase of the TK group and FGFR family. It is a cell-surface receptor for fibroblast growth factors and is critical for cell proliferation regulation, differentiation, migration and apoptosis. It is involved in differentiation and proliferation of osteoblasts and keratinocytes. It is activated by binding of fibroblast growth factor (FGF), which induces dimerization and autophosphorylation. Phosphorylation of Y769 increases phosphotransferase activity and induces interaction with FRS2 and PLCG1. It activates several signalling cascades, such as the MAPK and Akt1 pathway. Missense mutations are associated with ligand independent activation of TK25 (FGFR2) or an activating autocrine signalling loop. Overexpressed TK25 activates STAT1. FGFR2 is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. SNP in intron 2 of FGFR2 has been shown to be significantly associated with breast cancer. Mutations and gene amplifications are involved in various human cancers. Overexpression has been associated with tumourigenesis. Certain missense mutations have been associated with breast, ovarian, endometrial, prostate, bladder, gastric and lung cancers.